Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to  Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 May 2023

Li Jiamo, Yao Xingyu, Qiu Longjue, Zhang Ru, Wang Gang

Abstract excerpt

With the development of precision medicine for lung cancer, targeted therapy has greatly improved the survival and prognosis of patients with advanced non-small cell lung cancer (NSCLC), but the occurrence of acquired drug resistance ultimately leads to patients with no targeted drugs available and no standard treatment options for this group of patients afterwards. The emergence of immune checkpoint inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37316449
DOI: 10.3779/j.issn.1009-3419.2023.101.17
PMCID: PMC10273152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].PMID 37316449Read ↗

[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].Semantic proximity Read ↗

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors].Semantic proximity Read ↗

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations.Semantic proximity Read ↗

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR-TKIs Resistance.Semantic proximity Read ↗

The advanced research of immunotherapy in Epidermal growth factor receptor mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity Read ↗

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity Read ↗

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions.Semantic proximity Read ↗

[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.